<code id='7F31AD28A6'></code><style id='7F31AD28A6'></style>
    • <acronym id='7F31AD28A6'></acronym>
      <center id='7F31AD28A6'><center id='7F31AD28A6'><tfoot id='7F31AD28A6'></tfoot></center><abbr id='7F31AD28A6'><dir id='7F31AD28A6'><tfoot id='7F31AD28A6'></tfoot><noframes id='7F31AD28A6'>

    • <optgroup id='7F31AD28A6'><strike id='7F31AD28A6'><sup id='7F31AD28A6'></sup></strike><code id='7F31AD28A6'></code></optgroup>
        1. <b id='7F31AD28A6'><label id='7F31AD28A6'><select id='7F31AD28A6'><dt id='7F31AD28A6'><span id='7F31AD28A6'></span></dt></select></label></b><u id='7F31AD28A6'></u>
          <i id='7F31AD28A6'><strike id='7F31AD28A6'><tt id='7F31AD28A6'><pre id='7F31AD28A6'></pre></tt></strike></i>

          hotspot

          hotspot

          author:hotspot    Page View:75
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          Moonlake's readout produced a cash windfall. Risks remain
          Moonlake's readout produced a cash windfall. Risks remain

          MollyFerguson/STATFortwodaysstartingonSunday,MoonlakeImmunotherapeuticshappilycrunchednumbersandshar

          read more
          The Readout: Lenmeldy, GLP
          The Readout: Lenmeldy, GLP

          AdobeTodayistheinauguralpublishingdayforAdam’sBiotechScorecard—asubscriber-onlynewsletterofferingsen

          read more
          In age of alternative facts, a scholarly course on calling out crap
          In age of alternative facts, a scholarly course on calling out crap

          Screenshotviacallingbullshit.orgTiredofalternativefacts,fakenews,andbreathlesshyperbole,twoprofessor

          read more

          States should stop sabotaging methadone treatment reform

          Somearguethattakingmethadoneathomeisfarbetterthantrudgingtoacliniceveryday.KevinD.Liles/APSincetheFo